Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entrada Therapeutics filings document a clinical-stage biopharmaceutical issuer developing genetic medicines that engage intracellular targets. Recent Form 8-K reports furnish quarterly and annual financial results, cash and marketable-securities updates, and corporate updates related to its Duchenne muscular dystrophy franchise, ocular disease pipeline and partnered VX-670 program for myotonic dystrophy type 1.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and amendments to the company’s stock option and employee stock purchase plans. The filings also identify TRDA common stock listed on The Nasdaq Global Market, emerging growth company status, Regulation FD disclosures and governance matters tied to equity compensation and stockholder voting.
On 06/18/2025, Entrada Therapeutics (TRDA) filed a Form 4/A amending its prior insider-trading report. The filing discloses that director Peter S. Kim bought an additional 25,000 common shares on 05/13/2024 at a weighted-average price of $14.6804. This transaction was omitted from the original Form 4 filed on 05/16/2024, which had already reported a separate 25,000-share purchase on 05/14/2024 at $14.5869.
After including both purchases, Kim now directly owns 117,412 TRDA shares. No derivative securities were reported. The amendment corrects share totals and indicates that the director accumulated 50,000 shares over two consecutive trading days, a potential sign of insider confidence despite the minor reporting lapse.